RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
年轻与老年结直肠癌患者在治疗和生存上的差异
英文原题：Differences in treatment and survival in young and elderly patients with colorectal cancer.
查看英文原题
Differences in treatment and survival in young and elderly patients with colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
尽管疾病临床分期更晚，但在这项全国性队列中，年轻 CRC 患者的生存优于老年 CRC 患者。
中文摘要
方法
本回顾性研究分析了全国 484 例年轻患者（18–40 岁）和 14,647 例老年患者（66–75 岁）的术前管理、治疗及总生存期数据。使用 Cox 回归模型计算校正后的总生存期风险函数。
结果
不同年龄组的手术治疗差异不大，但年轻患者接受更多肿瘤治疗，且按分期划分的 5 年总生存率优于老年患者。校正模型中，I–III 期年轻患者的风险比在结肠癌中为 0.67（95% 置信区间 [CI]：0.48–0.95），在直肠癌中为 0.61（95% CI：0.37–0.99）。
结论
尽管年轻 CRC 患者临床分期更晚，在该全国队列中的生存仍优于老年 CRC 患者。 资助：研究由 Krista og Viggo Petersens Fond、Civilingeniør Bengt Bøgh og Hustru Inge Bøghs Fond，以及 Vejle 医院 Ane Mette Nielsen 遗产用于医学研究的基金资助。 试验注册：项目获 DCCG（2013-03）、丹麦数据保护局（2008-58-0035）和丹麦南部地区科学伦理委员会（S-20130079）批准。
展开英文摘要原文
METHODS
In a retrospective study design, we analysed data on pre-operative management, treatment and overall survival in a national cohort of 484 young (18-40 years) and 14,647 elderly (66-75 years) CRC patients. Cox regression models were used to calculate adjusted hazard functions of overall survival.
RESULTS
Surgical treatment did not differ markedly between age groups, but young patients received more oncological treatment and had a better stage-specific five-year overall survival than elderly patients. In an adjusted model, the hazard ratio for young patients with stage I-III disease was 0.67 (95% confidence interval (CI): 0.48-0.95) for colon cancer; 0.61 (95% CI: 0.37-0.99) for rectal cancer.
CONCLUSION
Despite more advanced clinical stages of disease, young CRC patients had a better survival than elderly CRC patients in this national cohort. FUNDING: The study was funded by Krista og Viggo Petersens Fond; Civilingeni r Bengt B gh og Hustru Inge B ghs Fond; and Arvekapitalen efter Ane Mette Nielsen til l gevidenskabelig forskning ved Vejle Sygehus. TRIAL REGISTRATION: The project was approved by DCCG (2013-03), the Danish Data Protection Agency (2008-58-0035) and the Regional Scientific Ethical Committee for Southern Denmark (S-20130079).
论文信息
- 作者
- Frostberg E、Lindeberg J、Sørensen FB、Rahr HB
- 单位
- Department of Surgery, Colorectal Cancer Centre South, University Hospital of Southern Denmark - Vejle Hospital.Denmark
- 期刊
- Danish medical journal2022 May 16
- 原文标识
- PubMed 35670424